dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Ulldemolins Iglesias, Anna |
dc.contributor.author | Seras Franzoso, Joaquin |
dc.contributor.author | Andrade, Fernanda |
dc.contributor.author | Abasolo Olaortua, Ibane |
dc.contributor.author | Gener, Petra |
dc.contributor.author | Schwartz Navarro, Simon |
dc.contributor.author | Rafael, Diana |
dc.date.accessioned | 2021-12-21T13:47:52Z |
dc.date.available | 2021-12-21T13:47:52Z |
dc.date.issued | 2021-03-19 |
dc.identifier.citation | Ulldemolins A, Seras-Franzoso J, Andrade F, Rafael D, Abasolo I, Gener P, et al. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resist. 2021 Mar 19;4:44–68. |
dc.identifier.issn | 2578-532X |
dc.identifier.uri | https://hdl.handle.net/11351/6722 |
dc.description | Sistemes d'administració de fàrmacs; Resistència; Tractament del càncer |
dc.language.iso | eng |
dc.publisher | OAE Publishing |
dc.relation.ispartofseries | Cancer Drug Resistance;4 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Quimioteràpia - Complicacions |
dc.subject | Nanomedicina |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Nanomedicine |
dc.subject.mesh | Drug Resistance |
dc.title | Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.20517/cdr.2020.59 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | nanomedicina |
dc.subject.decs | resistencia a medicamentos |
dc.relation.publishversion | https://doi.org/10.20517/cdr.2020.59 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Ulldemolins A, Seras-Franzoso J] Grup de Distribució i Orientació de Fàrmacs, Centre de Recerca en Biologia Molecular i Bioquímica per a Nanomedicina (CIBBIMNanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Andrade F, Rafael D] Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza 50009, Spain. [Abasolo I, Gener P, Schwartz Jr S] Grup de Distribució i Orientació de Fàrmacs, Centre de Recerca en Biologia Molecular i Bioquímica per a Nanomedicina (CIBBIMNanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Zaragoza 50009, Spain |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |